María José Juan-Fita

5PUBLICATIONS
56CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Oct 29, 2025
Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 Study.

Francesco Massari, Matteo Rosellini, Bohuslav Melichar

|Feb 17, 2025
Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial.

Xavier Garcia-Del-Muro, Begoña P Valderrama, Ana Medina-Colmenero

|Oct 26, 2024
Ultralow Prostate-Specific Antigen (PSA) Levels and Improved Oncological Outcomes in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Patients Treated with Apalutamide: A Real-World Multicentre Study.

Alicia López-Abad, Mario Belmonte, Miguel Ramírez Backhaus

|Nov 14, 2023
Phase II Trial Evaluating Olaparib Maintenance in Patients with Metastatic Castration-Resistant Prostate Cancer Responsive or Stabilized on Docetaxel Treatment: SOGUG-IMANOL Study.

María José Juan Fita, Urbano Anido Herranz, María José Mendez-Vidal

|Feb 13, 2020
Eastern Spanish experience with nivolumab in metastatic renal cell carcinoma.

J-F M José, M Jose, R Silverio

Pageof 1

Frequent Collaborators

1 joint publications

María José Mendez-Vidal

1 joint publications

José Muñoz-Langa

1 joint publications

Juan Sepúlveda-Sánchez

1 joint publications

Begoña Mellado